An FDA inspection can arrive with as little as 24 hours' notice — and in some cases, no notice at all. For pharmaceutical manufacturers operating under 21 CFR Parts 210 and 211, inspection readiness is not a sprint you run in the weeks before a scheduled audit. It is the daily discipline of maintaining cGMP-compliant.
Be 483-Ready Every Day — Not Just Before an Inspection
iFactory keeps your electronic records FDA-defensible — timestamped, attributable, and audit-trail-locked — so when an investigator walks in, your documentation is already complete. Book a demo to see it on your pharma QMS.
Facility & Equipment Readiness
Facility and equipment observations are among the most frequently cited categories in FDA Form 483s. Investigators walk the production floor before reviewing documentation — and what they observe sets the tone for the entire inspection. A facility that appears controlled, properly labeled, and well-maintained creates a fundamentally different investigator impression than one with unlabeled containers,.
Building Design
Separate areas for different operations. Layout prevents contamination and mix-ups. Size adequate for controlled operations.
HVAC & Air Systems
HVAC qualified and maintained. Environmental monitoring records current. Differential pressure logs completed and within spec.
Equipment Qualification
All production equipment qualified (IQ/OQ/PQ). Qualification records available. Equipment changes documented through change control.
Cleaning & Maintenance
Cleaning validation records available for all product-contact equipment. Cleaning SOPs followed and documented. Equipment logbooks complete.
Computerized Systems
Systems validated. Audit trails active and unmodified. Backup procedures documented and tested. Access controls current.
Quality Control Unit
QC has documented authority over all release decisions. Independence from production maintained. SOPs current and followed as written.
Documentation & Batch Record Readiness
Documentation is where FDA investigations live. A plant that manufactures perfectly but documents poorly will receive 483 observations. A plant that can produce every requested record promptly, accurately, and completely — with no blank fields, no unexplained corrections, and no gaps in the audit trail — demonstrates a controlled quality system. Batch record readiness means.
| Document Type | CFR Reference | Readiness Check | Common 483 Finding |
|---|---|---|---|
| Master Batch Records | 21 CFR 211.186 | Current revision, complete, approved by QC | Outdated revision in production use |
| Executed Batch Records | 21 CFR 211.188 | No blanks, all steps signed and dated contemporaneously | Blank fields, late entries, unsigned steps |
| Laboratory Records | 21 CFR 211.194 | Original data retained, calculations verified, OOS documented | OOS results invalidated without assignable cause |
| SOPs / Written Procedures | 21 CFR 211.100 | Current revision at point of use, superseded versions removed | Obsolete SOPs in use; procedures not followed as written |
| Change Control Records | 21 CFR 211.100 | All changes documented, impact assessed, validation completed | Undocumented process changes; no impact assessment |
Data Integrity — ALCOA+ Requirements
Data integrity is FDA's most actively enforced cGMP concern and the single leading cause of Warning Letters against pharmaceutical manufacturers globally. Every GMP record must meet the ALCOA+ standard: Attributable, Legible, Contemporaneous, Original, Accurate — plus Complete, Consistent, Enduring, and Available. FDA treats data integrity violations as fraud indicators, not simple documentation errors, and the.
Every entry traceable to the person who made it. Shared login credentials are an automatic 483 observation.
Corrections with a single line through original, initialed and dated. Never use correction fluid or overwriting.
Data recorded at the time the activity occurs. Back-filled or pre-dated entries indicate data integrity failure.
First capture is the record of truth. Transcription from scratch paper to official records is a violation.
All data — including OOS results and failed tests — must be retained. Selective retention constitutes fraud.
CAPA System Readiness
The CAPA system reveals whether an organization genuinely learns from its quality problems. FDA investigators examine CAPA health early in every inspection — not because it is the most glamorous part of the QMS, but because a backlog of overdue CAPAs, repeat findings for the same root cause, or CAPAs closed without effectiveness verification all.
Confirm each open CAPA has a documented owner, due date, root cause, and action plan. Overdue CAPAs require a documented extension justification.
Root cause analyses use a defined methodology. "Human error" alone is never acceptable — the systemic enabling condition must be identified.
Every closed CAPA requires documented evidence that the corrective action prevented recurrence before formal closure.
Review CAPA data for recurring root causes. Repeat findings for the same root cause indicate systemic failure to address underlying conditions.
OOS Handling & Lab Controls
Out-of-specification result handling is consistently a top-five Warning Letter observation category. Any deviation from FDA's 2006 OOS Guidance — including retesting without a documented assignable cause, analyst-initiated retests without protocol authorization, or averaging results that include an OOS value to reach a passing conclusion — is treated as a data integrity violation, not a procedural.
Analyst and supervisor review the original test for documented laboratory error. If confirmed: retest with documentation. If none found: proceed to.
Production records, process parameters, material review, and reserve sample testing conducted under an approved protocol. All results documented with statistical justification.
QC unit makes the final disposition with full investigation record attached. CAPA initiated if a systemic cause is identified.
FDA Readiness Is a Culture, Not a Checklist Sprint
Organizations that receive clean FDA inspections share one defining characteristic: their quality systems operate the same way whether an investigator is present or not. The five areas above — facility readiness, documentation, data integrity, CAPA, and laboratory controls — cover the highest-risk categories consistently cited in 483s and Warning Letters. A digital QMS platform makes.
FDA Inspection Readiness Checklist — 25 Items
Use this checklist to verify FDA inspection readiness across all cGMP areas. Each row maps to a 21 CFR requirement.
| # | Checklist Item | Type | Priority | Photo | Required | Critical |
|---|---|---|---|---|---|---|
| 1 | All production equipment qualified (IQ/OQ/PQ) — records available and current | Pass/Fail | High | ✓ | ✓ | ✓ |
| 2 | HVAC systems qualified — EM records current, differential pressure logs complete | Pass/Fail | High | — | ✓ | ✓ |
| 3 | Cleaning validation records available for all product-contact equipment | Pass/Fail | High | ✓ | ✓ | ✓ |
| 4 | Computerized systems validated — audit trails active, access controls current | Pass/Fail | High | — | ✓ | ✓ |
| 5 | QC unit has documented authority for all release decisions — independent of production | Pass/Fail | High | — | ✓ | ✓ |
| 6 | Equipment logbooks current and complete — maintenance on schedule | Pass/Fail | Med | — | ✓ | — |
| # | Checklist Item | Type | Priority | Photo | Required | Critical |
|---|---|---|---|---|---|---|
| 1 | Master Batch Records at current revision — no superseded versions in use | Pass/Fail | High | ✓ | ✓ | ✓ |
| 2 | Executed Batch Records — no blank fields, all steps signed and dated contemporaneously | Pass/Fail | High | ✓ | ✓ | ✓ |
| 3 | Laboratory Records — original data retained, OOS results documented and investigated | Pass/Fail | High | — | ✓ | ✓ |
| 4 | SOPs current at point of use — obsolete SOPs removed from all areas | Pass/Fail | High | — | ✓ | ✓ |
| 5 | Change control records complete — impact assessed, validation completed | Pass/Fail | High | — | ✓ | ✓ |
| # | Checklist Item | Type | Priority | Photo | Required | Critical |
|---|---|---|---|---|---|---|
| 1 | No shared login credentials — all entries attributable to individual user with timestamp | Pass/Fail | High | — | ✓ | ✓ |
| 2 | Corrections made with single line-through, initialed and dated — no correction fluid | Pass/Fail | High | ✓ | ✓ | ✓ |
| 3 | No evidence of back-filling, pre-dating, or transcription from scratch paper | Pass/Fail | High | — | ✓ | ✓ |
| 4 | All results retained including OOS, failed tests, and aberrant readings | Pass/Fail | High | — | ✓ | ✓ |
| 5 | Audit trail review performed routinely — anomalies investigated and documented | Pass/Fail | High | — | ✓ | ✓ |
| # | Checklist Item | Type | Priority | Photo | Required | Critical |
|---|---|---|---|---|---|---|
| 1 | All open CAPAs have documented owner, due date, root cause, and action plan | Pass/Fail | High | — | ✓ | ✓ |
| 2 | Root cause uses defined methodology — 'human error' not accepted as sole cause | Text | High | — | ✓ | ✓ |
| 3 | No overdue CAPAs without documented extension justification | Pass/Fail | High | — | ✓ | ✓ |
| 4 | Effectiveness verification completed with objective evidence before CAPA closure | Pass/Fail | High | — | ✓ | ✓ |
| 5 | Recurring findings trended — systemic root causes identified and addressed | Pass/Fail | Med | — | ✓ | — |
| # | Checklist Item | Type | Priority | Photo | Required | Critical |
|---|---|---|---|---|---|---|
| 1 | Phase I lab investigation documented — specific assignable cause identified or ruled out | Pass/Fail | High | — | ✓ | ✓ |
| 2 | Phase II manufacturing investigation conducted before any retest authorized | Pass/Fail | High | — | ✓ | ✓ |
| 3 | No results averaged to achieve pass — all individual results retained on record | Pass/Fail | High | — | ✓ | ✓ |
| 4 | QC disposition documented with full investigation record attached | Pass/Fail | High | — | ✓ | ✓ |
Frequently Asked Questions
What triggers an FDA inspection of a pharmaceutical facility?
FDA inspections are triggered by several factors: routine surveillance (most facilities inspected every 2–3 years under a risk-based schedule), pre-approval inspections before an NDA or ANDA approval, for-cause inspections triggered by a consumer complaint, adverse event, or recall, and follow-up inspections after a previous OAI.
What is the difference between a 483 observation and a Warning Letter?
A Form 483 is issued at the conclusion of an inspection and lists the investigator's observations of conditions that may constitute violations — it is not a final agency action. A Warning Letter is issued after FDA reviews the 483 and the manufacturer's response and.
How should we respond to a 483 observation?
Responses must be submitted within 15 business days and should address every observation with a root cause analysis, description of immediate corrective actions already taken, a CAPA plan with specific action items, owners and due dates, and supporting documentation. Vague commitments such as 'we will.
Make Your Quality Records Inspection-Ready Every Day
iFactory digitizes batch records, CAPAs, OOS investigations, and deviation reports with tamper-evident audit trails meeting 21 CFR Part 11 requirements. Book a 30-minute demo to walk through your inspection readiness workflow.
.jpg)
